
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67726
Pathology
Evidence of Programmed Death-Ligand 1 Expression in a Highly Inflammatory Prostate: A Literature Review and Our Experience
Muacevic Alexander
Adler John R
Koleva Maria 1
Mollova-Kyosebekirova Angelina 1
Dikov Dorian 2
1 Department of General and Clinical Pathology, Medical University of Plovdiv, Plovdiv, BGR
2 Department of Pathology, Jossigny Hospital, Jossigny, FRA
Maria Koleva mariya.koleva@mu-plovdiv.bg
25 8 2024
8 2024
16 8 e6772625 8 2024
Copyright © 2024, Koleva et al.
2024
Koleva et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/255797-evidence-of-programmed-death-ligand-1-expression-in-a-highly-inflammatory-prostate-a-literature-review-and-our-experience
Chronic inflammation (CI), a common finding in the human prostate, is associated with the most frequent socially important prostate diseases: prostatitis, benign prostatic hyperplasia, and prostate adenocarcinoma. Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) expression are induced on the surface of immune and epithelial cells of healthy and tumor tissues in response to various cytokines. Here, we provide a comprehensive review of the PD-1/PD-L1 pathway in the non- and peri-tumoral inflammatory prostate, focusing on the structure and expression of PD-L1 and the diverse biological functions of PD-L1 signaling in health, high-grade CI (National Institutes of Health, category IV prostatitis or histologic prostatitis), and immune-related diseases, including autoimmunity, tumor microenvironmental immunity, and immune privilege. This review explores the possible pathophysiological interpretations of clearly visible, selective, and strong PD-L1 expression in the immuno-inflammatory-induced and related, histologically distinct sites of this expression: the ductal lymphoepithelial lesions and prostatic granulomas.

inflammation
pd-l1
prostate
lymphoepithelial lesions
prostatitis
==== Body
pmcIntroduction and background

Chronic inflammation (CI) is frequently diagnosed in the human prostate. It is associated with prevalent and socially significant prostate diseases, including prostatitis, benign prostatic hyperplasia (BPH), and prostate adenocarcinoma (PCa). Extensive epidemiological, histopathological, and molecular pathological evidence underscores the pivotal role of inflammation in the development of these conditions [1,2]. In contrast to the urologist, the pathologist defines prostatitis as “more” inflammatory cells within the prostatic parenchyma [3]. The prostate has an important lymphoepithelial component responsible for genitourinary mucosal immunity, leading to the concept of prostate-associated lymphoid tissue (PALT) [4]. PALT shares immunological and microarchitectural features with secondary lymphoid organs like tonsils, particularly in terms of the lymphoid component. However, research on prostatic epithelial changes remains limited. Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) expression are induced in both immune and epithelial cells in healthy and tumor tissues in response to various cytokines. The PD-L1 expression in benign prostatic tissue is a new field of research that can clarify the crucial role of CI in the development of socially important prostate diseases via a specific inflammatory and immunosuppressive microenvironment. PD-L1 expression is rare in primary PCa [5-7]. The marker is rarely investigated in the non-tumoral prostatic lesions. Limited data showed a PD-L1 expression associated with chronic indefinite inflammatory infiltrate [5-7]. Also, the contribution of the PD-1/PD-L1 axis in immune responses is poorly understood in prostatic CI. Investigating prostatic inflammatory histopathology for years, we conducted a study to quantitatively and qualitatively assess the PD-L1 (1:200, clone QR1, BIOCYC, Potsdam, Deutschland) immunohistochemical expression in 152 cases of various forms of CI of the prostate: National Institutes of Health, category IV prostatitis or histologic prostatitis (HP), various types of granulomatous prostatitis (GP), and the reactive lymphoid infiltrates near of BPH and PCa [8,9]. HP was classified as low or high grade (LG, HG) based on inflammatory severity [3,10]. Control groups included non-inflammatory autopsy prostates with no documented illness and prostates of newborns and prepubescent children [8,9].

Review

PD-L1 expression in benign ductal lymphoepithelial lesions in HG-HP

Strong and selective PD-L1 immunoreactivity was identified in the epithelium of morphologically distinct ductal structures, known as benign lymphoepithelial lesions (LEL), [8] within prostates affected by HP. Also, PD-L1 positivity in immune cells surrounding LEL, as well as in intraluminal macrophages (Figure 1).

Figure 1 PD-L1 expression in HG-HP in serial sections.

The epithelium of the lymphoepithelial lesion showed selective and strong membranous immunoexpression of programmed death-ligand 1, not needing a special indication with arrows. Immunohistochemistry anti-programmed death-ligand 1, x200.

HG: high grade; HP: histologic prostatitis; PD-L1: programmed death-ligand 1

Image credits: Dr. Dorian Dikov

Lymphoepithelial lesions (LEL) are distinct morphological changes in the ductal epithelium in the glandular organs. It is a histological finding seen in lymphoma of mucosa-associated lymphoid tissues (MALT) and benign inflammatory diseases with reactive or autoimmune pathogenesis [11-15]. LEL is defined as clusters of three or more lymphoid cells causing alteration of the epithelium, along with histological changes within epithelial cells, including pronounced eosinophilia (Figure 2) [11].

Figure 2 Chronic HG prostatic inflammation.

Chronic high-grade (HG) prostatic inflammation with infiltration of lymphocytes affecting multiple prostatic ducts, associated with strongly eosinophilic epithelium, fully corresponding to programmed death-ligand 1-positive lymphoepithelial lesion from Figure 1; pronounced PD-L1 expression was also found in intra-luminal macrophages. Haematoxylin-eosin-saffron, x200.

PD-L1: programmed death-ligand 1

Image credits: Dr. Dorian Dikov

In malignant LEL found in marginal zone lymphomas, they are profuse, exhibit damage changes, and contain large, atypical centrocyte-like B-lymphoid cells [11]. In inflammatory diseases observed in other organs, benign LEL are small, non-destructive, and contain mature intra-epithelial lymphocytes (IEL) often with a dominance of T-cells [12,15]. We provide qualitative and quantitative analysis of LEL in the context of inflammatory human prostate conditions [8]. Prostatic LEL have no diagnostic organ specificity, even though they are a constant finding in HG-HP. Our statistical analysis revealed a strong correlation between the PD-L1-positive LEL and HG-HP (p<0.001, Fisher’s exact test) [8]. There was no significant PD-L1 expression or LEL in the control cases [8]. It is also discovered that intra-epithelial lymphocytes in both normal and inflamed prostates are primarily T-cells [16]. This peeks the interest in observation of PD-L1 in LEL. Expression of PD-L1 was also confirmed in the ductal epithelium of LEL in patients with CI, but not in normal or non-inflammatory prostate. This PD-L1 expression pattern correlates with the degree of lymphocytic inflammatory infiltration, resembling patterns seen in certain classical autoimmune diseases like Sjögren's syndrome [17]. The immune checkpoints, which are T-cell inhibitory molecules, prevent the activation of organ-specific antigen-reactive T-cells. To prevent tissue damage during inflammation, PD-L1 is normally overexpressed [18]. Unusual positivity for PD-L1 has been detected in various inflammatory conditions, including Helicobacter pylori+ chronic gastritis, bowel disease, salivary gland Sjögren’s syndrome, and celiac disease [13,19]. Prostatic ductal LELs are PD-L1-positive like these in autoimmune pancreatitis, chronic inflammatory diseases, and tonsillar crypts lymphoepithelium of adenoids (Waldeyer’s ring), the best external positive control in daily pathology practice (Figure 3).

Figure 3 PD-L1 expression in tonsillar crypts lymphoepithelium of adenoids (external positive control). Immunohistochemistry anti-PD-L1, x200.

PD-L1: programmed death-ligand 1

Image credits: Dr. Dorian Dikov

Our speculation revolves around the notion that PD-L1 expression in LEL represents an immune response designed to curb persistent T-cell activation, thus preventing tissue damage and autoimmune T-cell-mediated prostatitis. This “adaptive or innate immune resistance” mechanism (immune suppressive microenvironment) may provide insights into the scarcity of intra-tumoral lymphocytic infiltration and PD-L1 expression in PCa, always with CI [20]. Our findings also highlight that LEL formation occurs in adult life and forms an integral part of the PALT and of the inflammatory prostatic microenvironment [8].

PD-L1 expression in granulomatous prostatitis 

In our previous study, a notable finding was the elevated PD-L1 expressions in GP [9], which contributes to enriching the profile of GP. PD-L1 expression is strong and membranous in both localized and diffuse granulomatous prostatic inflammation (Figure 4, 5) [9].

Figure 4 Foci of localized GP, haematoxylin-eosin-saffron, x100.

GP: granulomatous prostatitis

Image credits: Dr. Dorian Dikov

Figure 5 PD-L1 expression in GP in serial sections.

Strong programmed death-ligand 1 (PD-L1) expression in the foci of localized granulomatous prostatitis.

GP: granulomatous prostatitis

Image credits: Dr. Dorian Dikov

In all etiological forms of GP (HG by definition), the expression of PD-L1 is selective within the areas of macrophageal/epithelioid granulomatous inflammation. In GP, the PD-L1 staining was generally easy to interpret, with a combined positive score (CPS) between 75 and 97 [9]. GP manifests as a self-limited inflammatory process, typically presenting with clinical symptoms such as low-grade fever, dysuria, and frequency [21,22].Microscopically, this is characterized by diffuse lobular chronic inflammation with infiltration of macrophages, epitheliod macrophages, multinucleated giant cells, and granuloma formation [23]. The etiological classification of GP encompasses nonspecific granulomatous prostatitis (NSGP), infectious granulomas (Mycobacterial: Bacillus Calmette-Guérin (BCG), Mycobacterium tuberculosis, mycoses, and parasitoses), post-surgical granulomas, and systemic granulomatous prostatitis (sarcoidosis) [23]. GP is a microscopical diagnosis with particular attention given to differential diagnosis considerations, especially in distinguishing it from high Gleason grade PCa [24] and associated HG-HP [25]. The role that PD-L1 plays in the abnormally regulated T-helper immune responses observed in granulomatous inflammation is unclear. The selective expression of PD-L1 in epithelioid granulomatous lesions is a less-known fact in the daily practice of pathologists. Notably, Kubo T. et al., in the only published work, present the strong positivity of PD-L1 in some invasive granulomatous diseases, tuberculosis, sarcoidosis, Crohn’s disease, and foreign body granuloma [26]. Negativity in PD-L1 expression in our control cases (data not shown) and in other non-granulomatous macrophage-rich lesions shows that the staining is not a non-specific reaction and is related to the presence of PD-L1 protein in epithelioid histiocytes [9]. Epithelioid granulomas with multinucleated giant cells express PD-L1 provoked by IFNγ or TNFα. The same authors propose that these cytokines may play a common role in the formation of different types of granulomas [26]. From a general and immuno-pathological perspective, we can guess if the expression of PD-L1 in GP represents an immune response helping to prevent persistent T-cell activation, which could otherwise lead to severe tissue damage and autoimmune T-cell-mediated prostatitis [9].

PD-L1 as a diagnostic marker in HG-inflammatory prostate 

Diagnosis of HP and GP relies on histological examination, with a primary focus on distinguishing them from high-grade Gleason PCa [24,25]. In this context, PD-L1 proves to be helpful for identifying prostatic epithelioid granulomatous lesions. All our positive cases (LEL in HG-HP and GP) showed clearly visible strong PD-L1 immunoreactivity, easily noticeable even under scanning microscopic magnification, and sometimes the two PD-L1-positive lesions are found in close proximity (Figure 6).

Figure 6 The strong and selective PD-L1 immunoreactivity in HG-inflammatory prostate is easily noticeable even under scanning microscopic magnification.

The presence of four programmed death-ligand 1 (PD-L1)-positive stromal granulomas on the left side of the picture and one programmed death-ligand 1-positive lymphoepithelial lesion in the ductal epithelium in the right part (arrow). Immunohistochemistry anti-programmed death-ligand, x100. The strong and selective programmed death-ligand immunoreactivity in high-grade (HG) inflammatory prostate is easily noticeable even under scanning microscopic magnification: the presence of four programmed death-ligand-positive stromal granulomas on the left side of the picture and one programmed death-ligand-positive lymphoepithelial lesion in the ductal epithelium in the right part (arrow). Immunohistochemistry anti-programmed death-ligand 1, x100.

Image credits: Dr. Dorian Dikov

Except for LEL and GP-foci, the inflammatory cells in LG and HG-HP, BPH, tumor parenchyma, and stroma in PCa are negative for PD-L1 (data not shown) [9]. Prostatic ductal LEL are PD-L1-positive, like these in autoimmune pancreatitis of type 2 [27] and could probably serve as an immunomorphologic hallmark of the immunologic (autoimmune) phase of chronic prostatic inflammation.

Research Perspectives

The PD-L1 expression in ductal LEL as a marker of prostatic epithelial barrier. Given that the prostate is an organ constantly exposed to pathogens, its ability to mount an early response to such stimuli is crucial for survival. However, the characteristics of the antigens that promote HP [2] and PD-L1-positive LEL formation are poorly understood so far [8]. In our previous study, we believe we are taking a step forward in clarifying the pathogenesis of HP, describing qualitatively and quantitatively the prostatic PD-L1-positive LEL [8]. The epithelium overlying the ductal LEL changes its functional morphology and immunohistochemical profile (PD-L1 expression), in order to become specialized for the transport of antigens directly from the ductal lumen. It is very possible that this specialized PD-L1-positive ductal epithelium plays a critical role as a gateway to the prostatic parenchyma. It has been shown to serve as an entry portal for antigens, like small intestinal and nasopharyngeal lymphoid tissues [28-30]. It is obvious that LEL are basic patho- and morphogenic elements of HG-HP, reflecting morphologically the moment of epithelial barrier disruption (Figure 7).

Figure 7 General view of HG-HP with rupture of a ductal LEL and diffusion of the intraluminal substances among immune periductal cells. Haematoxylin-eosin-saffron; x50.

HG: high grade; HP: histologic prostatitis; LEL: lymphoepithelial lesions

Image credits: Dr. Dorian Dikov

Obviously, this is followed by the influx of luminal antigenic substances that interact with the immune periductal cells (autoimmunization), leading to dysbiosis of the prostate microbiome and increased susceptibility to infection. Once initiated, this process can establish a feed-forward mechanism leading to a chronic, persistent HG inflammatory state (HG-HP) [2]. However, the specific initiator of the process, causing epithelial breakdown and inflammation, remains undefined. Prostatic epithelium could be damaged or disrupted for various reasons, including urine reflux and intraprostatic spermatozoa (Figure 8), and corpora amylacea (Figure 9).

Figure 8 Damaged prostatic epithelium of ductal LEL in HG-HP.

Programmed death-ligand 1-positive lymphoepithelial lesion in close proximity with intraprostatic spermatozoa (on the left).

HG: high grade; HP: histologic prostatitis; LEL: lymphoepithelial lesions

Image credits: Dr. Dorian Dikov

Figure 9 Eroded LEL from intraluminal corpora amylacea, haematoxylin-eosin-saffron, x400.

LEL: lymphoepithelial lesions

Image credits: Dr. Dorian Dikov

The PD-L1 expression in HG-HP as a marker of immunosuppressive phenotype

The PD-1/PD-L1 axis constitutes an inhibitory pathway to moderate the mechanism of immune tolerance, providing immune homeostasis. The important immunosuppressive role of the PD-1/PD-L1 pathway in the tumor microenvironment and autoimmune diseases has been demonstrated [31]. In contrast to normal (inflammatory) macrophages (M1), tumor-associated macrophages (M2) favor local immunosuppression [32]. Along with CD163 expression (Figure 10), this immunosuppressive phenotype included PD-L1 positivity in M2 (Figure 11) [32].

Figure 10 M2 intraprostatic macrophages in HG-HP, showing immunosuppressive phenotype CD163+.

HG: high grade; HP: histologic prostatitis

Image credits: Dr. Dorian Dikov

Figure 11 M2 intraprostatic macrophages in HG-HP, PD-L1+.

HG: high grade; HP: histologic prostatitis; PD-L1: PD-L1: programmed death-ligand 1

Image credits: Dr. Dorian Dikov

The idea for the immunological independence of the prostate is based on factors such as the lack of afferent lymphatic vessels, a high incidence of occult carcinoma, the immunosuppressive properties of seminal plasma, and the normal low basal level of the intra-epithelial lymphocytes [16]. However, recent studies proved that the normal prostate is not an immunologically privileged organ; instead, it is a part of the mucosal immune system (MALT) [4,16]. In particular, the expression of PD-L1 in HG inflammatory prostate, both in the ductal epithelium of the LEL and in stromal and intra-glandular macrophages (M2), strongly suggests an immunosuppressive phenotype that developed in the course of CI [33]. This is a perfectly satisfactory explanation of this inflammatory-induced microenvironmental immune tolerance in the prostate. During inflammatory episodes in HG-HP or GP, when complete antigen elimination is inefficient, elevated PD-L1 expression remains high. The last is considered a sign of consumed T-cells [33]. Additional research is required to determine the potential role of immune checkpoint inhibitor treatments in the management of GP and HG-HP.

Conclusions

In conclusion, our results and literature review provide evidence that PD-L1 is not expressed in normal human prostate and that expression of PD-L1 is induced by HG prostatic CI. PD-L1 positivity is located in a specialized, distinct ductal structure called LEL. LEL is not observed in the normal human prostate. PD-L1-positive LEL are an integral part of PALT and are inducible by external factors in terms of HG CI. PD-L1-positive LEL presents an integral part of HG-HP. HP (NIH, category IV prostatitis) occurs in several histologic patterns, and we describe a new pattern in prostatic inflammation, characterized by the presence of PD-L1-positive LEL in close association with HG-CI. Like other organs, PD-L1-positive LEL in the human prostate can be considered a hallmark of tissue autoimmunity and probably reflects the immune/autoimmune phase of HP (NIH category IV prostatitis). The association between PD-L1-positive LEL and HG-CI reveals the aggressiveness grade of the subclinical HP (NIH category IV prostatitis).

Our results could serve as an accurate guide for the clinician. We believe that except for the aggressiveness grades of the inflammation, the presence of PD-L1-positive LEL should be noted in the pathologist’s report, especially in initial prostate biopsies, in order to help the timing of the further biopsy. We suggest that the presence of PD-L1-positive LEL must be added to the actual NIH-consensus grading classification system based on morphological criteria for chronic prostatic inflammation. The novel data suggest that PD-L1-positive LEL may be a key player in the pathophysiology and morphogenesis of HP (NIH, category IV prostatitis) by mediating the self-sustained inflammatory immune/autoimmune processes in this chronic subclinical disease. In GP epithelioid granulomatous and diffuse inflammatory infiltrates exhibit selectively high levels of PD-L1 expression. In GP, the presence of PD-L1-positive LEL and granulomatous inflammation facilitates easy identification and diagnosis when stained with PD-L1.

Disclosures

Author Contributions

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Angelina Mollova-Kyosebekirova, Dorian Dikov, Maria Koleva

Acquisition, analysis, or interpretation of data:  Angelina Mollova-Kyosebekirova, Dorian Dikov, Maria Koleva

Drafting of the manuscript:  Angelina Mollova-Kyosebekirova, Dorian Dikov, Maria Koleva

Critical review of the manuscript for important intellectual content:  Angelina Mollova-Kyosebekirova, Dorian Dikov, Maria Koleva

Supervision:  Angelina Mollova-Kyosebekirova, Dorian Dikov, Maria Koleva
==== Refs
References

1 Inflammation in prostate carcinogenesis Nat Rev Cancer De Marzo AM Platz EA Sutcliffe S 256 269 7 2007 17384581
2 The inflammatory microenvironment and microbiome in prostate cancer development Nat Rev Urol Sfanos KS Yegnasubramanian S Nelson WG De Marzo AM 11 24 15 2018 29089606
3 Consensus development of a histopathological classification system for chronic prostatic inflammation BJU Int Nickel JC True LD Krieger JN Berger RE Boag AH Young ID 797 805 87 2001 11412216
4 The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort Oncotarget Ness N Andersen S Khanehkenari MR 26789 26801 8 2017 28460462
5 Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer Medicine (Baltimore) Sharma M Yang Z Miyamoto H 0 98 2019
6 The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer Mol Ther Xu Y Song G Xie S 1958 1969 29 2021 33932597
7 PD-L1 positive lympho-epithelial lesions in inflammatory prostate Histol Histopathol Dikov D Koleva M Simitchiev K Baltov M Sarafian V 749 755 37 2022 35670049
8 Strong PD-L1 expression in granulomatous prostatitis Prostate Dikov D Koleva M Mollova A Fakirova A 1285 1289 83 2023 37357498
9 Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol Delongchamps NB de la Roza G Chandan V 1736 1740 179 2008 18343414
10 Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type of the ocular adnexa: retrospective single institution review of 95 patients Indian J Ophthalmol Lim SH Kang M Son J 273 277 59 2011 21666310
11 Autoimmune pancreatitis: current diagnostic criteria are suboptimal J Gastroenterol Hepatol Giday SA Khashab MA Buscaglia JM 970 973 26 2011 21299615
12 Benign lymphoepithelial lesions of the salivary glands JAMA Kelly DR Spiegel JC Maves M 71 75 101 1975
13 Lymphoepithelial lesion in the thyroid A non-specific histological finding Pathol Res Pract Matias-Guiu X Esquius J 296 300 187 1991 2068014
14 Lymphocytic mastitis and diabetic mastopathy: a molecular, immunophenotypic, and clinicopathologic evaluation of 11 cases Mod Pathol Valdez R Thorson J Finn WG Schnitzer B Kleer CG 223 228 16 2003 12640102
15 Intraepithelial lymphocytes in relation to NIH category IV prostatitis in autopsy prostate Prostate Dikov D Bachurska S Staikov D Sarafian V 1074 1084 75 2015 https://doi.org/10.1002/pros.22991 25917232
16 Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome J Rheumatol Kobayashi M Kawano S Hatachi S 2156 2163 32 2005 https://www.jrheum.org/content/32/11/2156.tab-article-info 16265694
17 PD-1 and its ligands in tolerance and immunity Annu Rev Immunol Keir ME Butte MJ Freeman GJ Sharpe AH 677 704 26 2008 18173375
18 Role of PD-L1 in gut mucosa tolerance and chronic inflammation Int J Mol Sci Chulkina M Beswick EJ Pinchuk IV 9165 21 2020 33271941
19 Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance Prostate Cancer Prostatic Dis Martin AM Nirschl TR Nirschl CJ 325 332 18 2015 26260996
20 Non-specific granulomatous prostatitis J Urol O’Dea MJ Hunting DB Greene LF 58 60 118 1977 875199
21 The clinical spectrum of granulomatous prostatitis: a report of 200 cases J Urol Stillwell TJ Engen DE Farrow GM 320 323 138 1987 3599248
22 Granulomatous prostatitis: distinction among allergic, nonspecific, and post-transurethral resection lesions Hum Pathol Epstein JI Hutchins GM 818 825 15 1984 6432674
23 Granulomatous prostatitis: clinical and histomorphologic survey of the disease in a tertiary care hospital Prostate Int Shukla P Gulwani HV Kaur S 29 34 5 2017 28352621
24 Histopathology of nonspecific granulomatous prostatitis with special reference to eosinophilic epithelial metaplasia: pathophysiologic, diagnostic and differential diagnostic correlations Indian J Pathol Microbiol Dikov DI Koleva MS Boivin JF Lisner T Belovezhdov VT Sarafian V 0 40 63 2020
25 Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy Hum Vaccin Immunother Kubo T Hirohashi Y Tsukahara T Kanaseki T Murata K Hasegawa T Torigoe T 1940 1942 17 2021 33570446
26 Autoimmune pancreatitis type 2: diagnostic utility of PD-L1 immunohistochemistry Am J Surg Pathol Gupta R Neyaz A Chougule A 898 906 43 2019 31135488
27 M cell-dependent antigen uptake on follicle-associated epithelium for mucosal immune surveillance Inflamm Regen Nakamura Y Kimura S Hase K 15 38 2018 30186536
28 Differentiation of epithelial cells to M cells in response to bacterial colonization on the follicle-associated epithelium of Peyer's patch in rat small intestine J Vet Med Sci Chin K Onishi S Yuji M 1023 1028 68 2006 17085879
29 M cells in antigen sampling in mucosal tissues Curr Top Microbiol Immunol Neutra MR 17 32 236 1999 9893353
30 The role of PD-1 signaling in health and immune-related diseases Front Immunol Chen RY Zhu Y Shen YY 1163633 14 2023 37261359
31 Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype Clin Transl Med Boibessot C Molina O Lachance G 0 12 2022
32 Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1 J Immunother Cancer Wen ZF Liu H Gao R 151 6 2018 30563569
33 Molecular and cellular insights into T cell exhaustion Nat Rev Immunol Wherry EJ Kurachi M 486 499 15 2015 26205583
